Niraparib
Niraparib
Niraparib (pronounced: nee-rah-PAH-rib) is a medication used in the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It is classified as a PARP inhibitor, which stands for Poly (ADP-ribose) polymerase inhibitors.
Etymology
The name "Niraparib" is derived from the combination of syllables that are commonly used in the naming of pharmaceutical drugs. The exact etymology is not known.
Usage
Niraparib is used to treat certain types of cancer, including ovarian, fallopian tube, and primary peritoneal cancer. It works by slowing the growth of cancer cells. Niraparib is usually given after at least two other cancer treatments have been tried without success.
Side Effects
Common side effects of Niraparib include nausea, constipation, headache, and tiredness. More serious side effects can include high blood pressure, shortness of breath, and severe nausea or vomiting. If these occur, it is important to contact a healthcare provider immediately.
Related Terms
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Fallopian tube cancer: A rare type of cancer that starts in the fallopian tubes.
- Primary peritoneal cancer: A rare type of cancer that starts in the peritoneum, the thin layer of tissue that covers the abdomen and several organs within it.
- PARP inhibitor: A type of drug that blocks an enzyme in cells called PARP, which helps repair DNA when it becomes damaged. Blocking PARP can cause cancer cells to die.
External links
- Medical encyclopedia article on Niraparib
- Wikipedia's article - Niraparib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski